



(12) **DEMANDE DE BREVET CANADIEN**  
**CANADIAN PATENT APPLICATION**  
(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/05/14  
(87) Date publication PCT/PCT Publication Date: 2018/11/22  
(85) Entrée phase nationale/National Entry: 2019/10/31  
(86) N° demande PCT/PCT Application No.: IL 2018/050523  
(87) N° publication PCT/PCT Publication No.: 2018/211498  
(30) Priorité/Priority: 2017/05/15 (US62/506,006)

(51) Cl.Int./Int.Cl. *A61K 35/28* (2015.01),  
*A61P 21/00* (2006.01), *C12N 5/0775* (2010.01)  
(71) Demandeur/Applicant:  
STEM CELL MEDICINE LTD., IL  
(72) Inventeurs/Inventors:  
MAROM, EHUD, IL;  
GRYNSPAN, FRIDA, IL;  
YUDIN, DIMA, IL  
(74) Agent: AVENTUM IP LAW LLP

(54) Titre : TRAITEMENT DE LA SCLEROSE EN PLAQUES AVEC DES CELLULES SOUCHES DERIVEES DU TISSU ADIPEUX  
(54) Title: TREATMENT OF MULTIPLE SCLEROSIS WITH ADIPOSE-DERIVED STEM CELLS

(57) **Abrégé/Abstract:**

Methods of treating progressive forms of multiple sclerosis are provided, comprising administering adipose-derived stem cells into the central nervous system (CNS). Further provided are improved methods for obtaining ADSCs, which are more cost effective and which provide higher yields compared to currently used methods.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau

(43) International Publication Date  
22 November 2018 (22.11.2018)



(10) International Publication Number  
WO 2018/211498 A1

- (51) International Patent Classification:  
A61K 35/28 (2015.01) C12N 5/0775 (2006.01)  
A61P 21/00 (2006.01)
- (21) International Application Number:  
PCT/IL2018/050523
- (22) International Filing Date:  
14 May 2018 (14.05.2018)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
62/506,006 15 May 2017 (15.05.2017) US
- (71) Applicant: STEM CELL MEDICINE LTD. [IL/IL]; 5  
Kiryat Mada Street, 9777605 Jerusalem (IL).
- (72) Inventors: MAROM, Ehud; 7 Aluf Kalman Magen  
Street, 6107079 Tel Aviv (IL). GRYNSPAN, Frida; 16  
Arbel Street, P.O. Box 84595, 90805 Mevaseret Zion  
(IL). YUDIN, Dima; 14/1 Izhak Tunik Street, 9779517  
Jerusalem (IL).
- (74) Agent: WEBB, Cynthia et al.; WEBB & CO., P.O. BOX  
2189, 7612101 REHOVOT (IL).
- (81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:  
— of inventorship (Rule 4.17(iv))

Published:  
— with international search report (Art. 21(3))

(54) Title: TREATMENT OF MULTIPLE SCLEROSIS WITH ADIPOSE-DERIVED STEM CELLS

(57) Abstract: Methods of treating progressive forms of multiple sclerosis are provided, comprising administering adipose-derived stem cells into the central nervous system (CNS). Further provided are improved methods for obtaining ADSCs, which are more cost effective and which provide higher yields compared to currently used methods.

## **TREATMENT OF MULTIPLE SCLEROSIS WITH ADIPOSE-DERIVED STEM CELLS**

### **FIELD OF THE INVENTION**

5           The present invention relates to treatment regimens for multiple sclerosis comprising administration of adipose-derived stem cells. In particular, the invention relates to treatment of progressive forms of multiple sclerosis using intra-ventricular or intrathecal administration of adipose-derived stem cells.

### **10 BACKGROUND OF THE INVENTION**

          Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) which typically occurs at young adults, more prevalent in women than in men. MS affects the ability of nerve cells in the brain and spinal cord to communicate with each other and control body functions. The clinical disability is linked to an inflammation  
15   of myelin, the protective sheath around the axons of the CNS, which is damaged due to an autoimmune attack and neurodegenerative processes. As a consequence, the white matter of the brain and spinal cord becomes scarred by focal lesions (plaques) leading to neurological dysfunction. There are several patterns of symptoms of MS. Most patients experience a relapsing-remitting (RRMS) course at the initial stage, characterized by  
20   unpredictable relapses followed by periods of partial or complete recovery (remission), which at some point becomes progressive (PMS). Such progressive MS is classified as secondary progressive MS (SPMS). Some patients experience a progressive course from the onset of symptoms, and such disease pattern is classified as primary progressive MS (PPMS).

25           Patients with relapsing-remitting MS are typically treated with corticosteroids during acute attacks (relapses), and with immunomodulatory- or immunosuppressive drugs to prevent new relapses and progression of disability. These include interferon beta (Avonex®, Rebif®, Betaseron®), glatiramer acetate (Copaxone®), dimethyl fumarate (Tecfidera®), fingolimod (Gilenya®) natalizumab (Tysabri®) and the chemotherapeutic  
30   agent mitoxantrone in more severe cases.

          Progressive forms of MS are sometimes treated using similar drugs, but treatment is mainly focused on managing symptoms and rehabilitation. All treatment options for MS are only partially effective.



A recent review highlights that progressive MS is an area where there is currently a paucity of available disease-modifying treatments (Clinical Medicine, 2016, Vol. 16(6), pages s53–s59). Ocrelizumab (OCREVUS<sup>TM</sup>) is a humanized anti-CD20 monoclonal antibody, which was granted Breakthrough Therapy Designation for PPMS by the Food and Drug Administration (FDA) in 2016 (Investor Update by Roche, Basel, February 17, 2016).

Mesenchymal stem cells (MSCs) for the treatment of autoimmune and/or neurodegenerative diseases:

MSCs are a source of multipotent self-renewing cells, originally identified in adult bone marrow. Naturally, they differentiate to produce osteoblasts, chondrocytes and adipocytes. MSCs provide an accessible source of multipotent stem cells alternative to embryonic stem (ES) cells. MSCs potentially circumvent the need for immunosuppression in cellular therapies since they can be derived from an autologous source and also because they are characterized by an immuno-privileged nature advantageous for allogeneic use.

MSCs based therapies have shown to be effective in preclinical studies for a number of indications including graft versus host disease, stroke, myocardial infarction, pulmonary fibrosis and autoimmune disorders. MSCs are also being extensively researched as a therapeutic tool against neurodegenerative diseases. MSCs have been discussed with regard to two aspects in the context of neurodegenerative diseases: their ability to transdifferentiate into neural cells under specific conditions and their neuroprotective and immunomodulatory effects. When transplanted into the brain, MSCs produce neurotrophic and growth factors that protect and induce regeneration of damaged tissue. Additionally, MSCs have also been explored as gene delivery vehicles, for example being genetically engineered to over express glial-derived or brain-derived neurotrophic factor in the brain. Clinical trials involving MSCs are currently underway for MS, ALS, traumatic brain injuries, spinal cord injuries and stroke.

Adipose-derived stem cells (ADSCs):

It has been shown over the past few decades that adipose tissue is in addition to its main function as an energy reservoir also an abundant resource for multipotent stromal cells (Zuk et al., Mol Biol Cell 2002; 13: 4279-4295).

WO 2010/045645 discloses methods of recovering adipose stem cells from adipose tissue.

US 8,021,882 discloses a method for producing stem cell conditioned media for the treatment of neurological insults, by providing a culture of adipose stem cells and collecting the supernatants thereof.

Constantin et al. (2009) *Stem Cells.*, 27(10):2624-35 studied intravenous  
5 administration of adipose-derived mesenchymal stem cells to mice in chronic experimental autoimmune encephalomyelitis (EAE).

Stepien et al. (2016) *Mediators of Inflammation*, vol. 2016, report a one-year follow-up of MS patients with RRMS or SPMS treated with autologous adipose stem cell injected intrathecally.

10 WO 2006/057003 discloses, *inter alia*, methods of stem cell therapy using bone marrow-derived stem cells in combination with glatiramer.

Aharoni et al. (2009) *J Neuroimmunol.*, 215(1-2):73-83 report about co-treatment of EAE-induced mice with muscle progenitor cells (MPCs), transplanted either intraventricularly or intraperitoneally, and glatiramer acetate.

15 There is a need in the art for improved methods for treating multiple sclerosis, particularly for patients with progressive forms of the diseases.

## SUMMARY OF THE INVENTION

The present invention provides according to some aspects therapies for multiple  
20 sclerosis (MS), including progressive MS, particularly primary progressive MS, using adipose-derived stem cells (ADSCs) administered into the central nervous system (CNS). The present invention further provides improved methods for obtaining ADSCs, which are more cost effective and which provide higher yields compared to currently used methods.

The present invention is based, in part, on the surprising effect of human ADSCs  
25 administered into the CNS on the clinical score in an animal model of chronic multiple sclerosis. The cells were found to be particularly effective in reducing the maximal disease score and, importantly, in slowing the progression of the disease. Advantageously, the cells were isolated using an improved method as exemplified herein below. The improved method, disclosed herein for the first time, involves freezing and thawing a sample of  
30 adipose tissue obtained by lipoaspiration, i.e. a lipoaspirate, before further processing. The improved method also avoids the need for applying a buffer to destroy red blood cells found in the lipoaspirate, as required by currently used methods. The improved method thus also eliminates subsequently separating the ADSCs from cell debris. It was



surprisingly found that even though a red blood cell lysis buffer is not applied, the resulting ADSCs sample grows as effectively as a sample isolated according to standard methods.

According to one aspect, the present invention provides a method of treating  
5 primary progressive multiple sclerosis comprising administering non-genetically modified human adipose-derived stem cells (hADSCs) into the central nervous system (CNS) of a subject in need thereof.

In some embodiments, the hADSCs are hADSCs obtained from human subcutaneous fat by:

- 10 (a) freezing a lipoaspirate;
- (b) thawing the lipoaspirate and dissociating with a tissue-dissociation enzyme or by mechanical disruption;
- (c) pelleting a cellular fraction comprising the hADSCs by centrifugation, and optionally washing the pellet with a suspension medium capable of supporting cell
- 15 viability and subjecting the suspension to at least one additional centrifugation;
- (d) resuspending the pellet obtained in step (c) in a suspension medium capable of supporting cell viability and selecting hADSCs from the population of cells in the resuspended pellet;
- (e) optionally conducting at least one filtration prior to the hADSC selection; and
- 20 (f) optionally culturing the hADSCs for at least 3 passages.

In some embodiments, the hADSCs are hADSCs obtained from human subcutaneous fat by: (i) freezing a lipoaspirate; (ii) thawing the lipoaspirate and dissociating with a tissue-dissociation enzyme or by mechanical disruption; (iii) pelleting a cellular fraction comprising the hADSCs by centrifugation; (iv) washing the pellet with an

25 isotonic buffer or culture medium and subjecting to a further centrifugation; (v) resuspending the pellet obtained in step (iv) in an isotonic buffer or culture medium and conducting at least one filtration; (vi) selecting hADSCs from the population of cells in the resuspended pellet; and (vii) culturing the hADSCs for at least 3 passages.

As disclosed herein, the method of obtaining ADSCs avoids the need for applying  
30 a buffer to cause lysis of red blood cells originally found in the lipoaspirate. Thus, in some embodiments, the lipoaspirate is processed to isolate adipose-derived stem cells without applying a red blood cells lysis buffer. According to these embodiments, the cellular

fraction comprising the hADSCs obtained following centrifugation is not exposed to a red blood cell lysis buffer.

According to another aspect, the present invention provides a method of injecting human adipose-derived stem cells (hADSCs) into the central nervous system (CNS) of a subject in need thereof, the method comprising obtaining hADSCs from human subcutaneous fat by:

- (a) freezing a lipoaspirate;
- (b) thawing the lipoaspirate and dissociating with a tissue-dissociation enzyme or by mechanical disruption;
- 10 (c) pelleting a cellular fraction comprising the hADSCs by centrifugation and optionally washing the pellet with a suspension medium capable of supporting cell viability and subjecting to at least one more centrifugation;
- (d) resuspending the pellet obtained in step (c) in a buffer or culture medium and conducting at least one filtration;
- 15 (e) selecting hADSCs from the population of cells in the resuspended pellet;
- (f) optionally culturing the hADSCs for at least 3 passages; and
- (g) injecting the hADSCs into the CNS of the subject.

According to a further aspect, the present invention provides a method for obtaining human adipose-derived stem cells (hADSCs) from human subcutaneous fat for administration to a subject in need thereof, the method consisting of:

- (a) freezing a lipoaspirate;
- (b) thawing the lipoaspirate and dissociating with a tissue-dissociation enzyme or by mechanical disruption;
- (c) pelleting a cellular fraction comprising the hADSCs by centrifugation, and
- 25 optionally washing the pellet with a suspension medium capable of supporting cell viability and subjecting the suspension to at least one additional centrifugation;
- (d) resuspending the pellet obtained in step (c) in a suspension medium capable of supporting cell viability and conducting at least one filtration;
- (e) selecting hADSCs from the population of cells in the resuspended pellet; and
- 30 (f) optionally culturing the hADSCs for at least 3 passages prior to their administration to the subject.

As disclosed herein, the cellular fraction comprising the hADSCs obtained following centrifugation is not exposed to a red blood cell lysis buffer.



In some embodiments, the hADSCs are selected by adherence to a cell culture vessel. In some embodiments the cells adhere to a plastic tissue culture vessel.

In some embodiments, freezing is carried out at  $-80^{\circ}\text{C}$  followed by vapor phase liquid nitrogen.

5 In some embodiments, the tissue-dissociation enzyme is selected from a collagenase, a dispase or a combination thereof. In some specific embodiments, the tissue-dissociation enzyme is a collagenase.

In some embodiments, the hADSCs are characterized by positive expression of CD44, CD73 and CD90 by at least 95% of the cells, positive expression of CD105 by at  
10 least 90% of the cells, and negative expression of CD45, CD19, CD11b and HLA-DR by at least 95% of the cells. According to some embodiments, the hADSCs are further characterized by positive expression of CD34 by 1-10% of the cells.

In some embodiments, the hADSCs are characterized by positive expression of CD44, CD73 and CD90 by at least 98% of the cells, positive expression of CD105 by at  
15 least 90% of the cells, and negative expression of CD45, CD19, CD11b and HLA-DR by at least 98% of the cells.

In some embodiments, at least 50% of the cells are positive for CD105, CD73, CD44 and CD90, and negative for CD45, CD19, CD11b and HLA-DR.

In some embodiments, the hADSCs are hADSCs cultured to a passage number  
20 between 3-10 prior to their administration. In additional embodiments, the hADSCs are hADSCs cultured to a passage number between 3-5 prior to their administration.

In some embodiments, the hADSCs are hADSCs cultured in a xeno-free medium prior to their administration.

According to some embodiments, the hADSCs are administered once.

25 According to other embodiments, the hADSCs are administered more than once, for example twice, three times, four times, etc. Each possibility represents a separate embodiment of the present invention. According to some embodiments, the hADSCs are administered once every 2-8 months. According to additional embodiments, the hADSCs are administered once every 3-12 months.

30 According to some embodiments, administering the hADSCs is by intrathecal administration.

According to other embodiments, administering the hADSCs is by intraventricular or intracerebroventricular (ICV) administration, namely into the brain ventricles.



According to some embodiments, the hADSCs are derived from human subcutaneous fat obtained by liposuction aspiration.

According to some embodiments, the hADSCs are autologous.

According to other embodiments, the hADSCs are allogeneic.

5 According to some embodiments, administering the hADSCs comprises administering about  $10^5$ – $3 \times 10^8$  cells per one administration.

The subject to be treated as described herein is typically a human. According to some embodiments, the methods and compositions of the present invention are useful for the treatment of multiple sclerosis, particularly progressive forms of multiple sclerosis  
10 (MS). Thus, according to some embodiments, the subject is suffering from MS. In some embodiments, the subject is a subject suffering from a progressive form of MS. In some specific embodiments, the progressive MS is secondary progressive MS. In additional specific embodiments, the progressive MS is primary progressive MS.

These and further aspects and features of the present invention will become  
15 apparent from the detailed description, examples and claims which follow.

## BRIEF DESCRIPTION OF THE FIGURES

**Figure 1:** ADSC dose response on EAE –Mean Clinical Score analysis up to day 28. All groups (n=10 / group, +/- standard error).

20 **Figure 2:** ADSC dose response on EAE –Mean Clinical Score analysis up to day 28. Vehicle compared to  $2 \times 10^5$  cell/animal. (n=10 / group, +/- standard error).

**Figure 3:** ADSC dose response on EAE –Mean Clinical Score analysis up to day 28. Comparison of  $1 \times 10^5$  cells,  $2 \times 10^5$  cell, and  $4 \times 10^5$  cells/animal. (n=10 / group, +/- standard error).

25 **Figure 4:** ADSC dose response on EAE – Weight analysis up to day 29. (n=10 / group, +/- standard error).

**Figure 5:** Effect of ADSCs cell dose on EAE – Mean AUC of Mean Clinical Score (disease burden) up to day 28. \*P<0.05 (n=10 / group, +/- standard error)

**Figure 6:** Effect of ADSCs dose on EAE – Mean Maximum Score analysis up to  
30 day 28. \*P<0.05 (n=10 / group, +/- standard error).

**Figure 7:** Cell surface marker expression of ADSCs as a function of passage number. The cells were isolated from adipose tissue and cultured as described in the

Examples section, and analyzed for the expression of the indicated markers. The results are the average +/- standard deviation of nine (9) samples.

**Figure 8:** SVF cell counting data following isolation with or without red blood cell lysis. (A) cells/ml; (B) % viability.

5 **Figure 9:** Cell counting data at passage 0 following isolation with or without red blood cell lysis. (A) cells/ml; (B) % viability.

**Figure 10:** SVF and ADSC yields as a function of initial volume of lipoaspirated tissue sample – 1<sup>st</sup> batch. Total number of viable cells immediately after SVF isolation (A), at P#0 (B), and at P#1 (C).

10 **Figure 11:** SVF and ADSC yields as a function of initial volume of lipoaspirated tissue sample – 2<sup>nd</sup> batch. Total number of viable cells immediately after SVF isolation (A), at P#0 (B), and at P#1 (C).

**Figure 12:** SVF and ADSC yields as a function of initial volume of lipoaspirated tissue sample – 3<sup>rd</sup> batch. Total number of viable cells immediately after SVF isolation  
15 (A), at P#0 (B), and at P#1 (C).

## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides according to some aspects therapies for multiple sclerosis (MS) including progressive MS using adipose-derived stem cells (ADSCs).

20 In some embodiments, a method of treating primary progressive multiple sclerosis comprising administering human adipose-derived stem cells (hADSCs) into the central nervous system (CNS) of a subject in need thereof is provided.

The inventors of the present invention have utilized the MOG induced EAE model for evaluation of the effect of adipose-derived mesenchymal stem cells on the disease  
25 outcome. MOG is a glycoprotein believed to be important in the process of myelination of nerves in the central nervous system (CNS). Immunization with MOG 35-55 peptide is generally used for induction of a chronic EAE in C57BL/6 mice. ADSCs were injected into the brain ventricles (ICV) of mice in which EAE has been induced using MOG. Mice were treated with various doses of stem cells.

30 The surprising observations disclosed herein for the first time demonstrate a clear effect of human ADSCs on chronic EAE, including clinical score, maximum mean disease score and disease progression.



The present invention thus provides treatment methods and regimens comprising administration of human mesenchymal adipose-derived stem cells to subjects suffering from progressive forms of multiple sclerosis. These treatments afford superior therapeutic efficacy for multiple sclerosis, compared to intravenous treatment with stem cells. The  
5 current treatment resulted in improved and prolonged effects as determined by various clinical scores.

At present methods and regimens for treatment of multiple sclerosis, comprising administration of adipose-derived stem cells are not yet proven effective and safe, nor are any treatments commercially available. Such therapies would be beneficial to many  
10 patients, particularly to those with advanced disease accompanied by neurological symptoms or physical disabilities. Specifically, this treatment will benefit patients with progressive forms of multiple sclerosis.

The term “treating” as used herein refers to prevention, suppression or alleviation of a symptom or of a plurality of symptoms after the onset of primary progressive or  
15 secondary progressive multiple sclerosis. In certain embodiments, the symptom is selected from the group consisting of impaired coordination, impaired walking capability, impaired balance, weakness of the leg, stiffness of the leg, impaired memory, impaired cognitive function, a difficulty to swallow, impaired vision, general fatigue, pain, impaired bladder function, impaired bowel function, and any combination thereof. Each possibility  
20 represents a separate embodiment of the invention.

In some particular embodiments, treating multiple sclerosis according to the present invention comprises slowing disease progression, i.e., slowing the progression of disability.

The “subject” to which the cells are administered is a mammal, typically a human.  
25 The subject according to some embodiments is suffering from a progressive form of multiple sclerosis, namely, diagnosed with a progressive form of multiple sclerosis.

The term “multiple sclerosis” as used herein refers to an auto-immune disease of the central nervous system which is accompanied by one or more of the symptoms described hereinabove. In some embodiments, the progressive MS is secondary  
30 progressive MS. In other embodiments, the progressive MS is primary progressive MS. In additional embodiments, the progressive MS is progressive relapsing MS.

According to some embodiments, the ADSCs are administered once. According to some embodiments, the ADSCs are administered multiple times, for example every 2-8 months, every 3-12 months, or less frequent.

According to some embodiments, the ADSCs are administered once every 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months. Each possibility represents a separate embodiment of the present invention.

#### Adipose-derived stem cells

The present invention utilizes adipose-derived mesenchymal stem cells. As used herein, the terms "adipose-derived mesenchymal stem cells" or "adipose-derived stem cells", abbreviated "ADSCs" or "hADSCs" (i.e., human adipose-derived stem cells), refer to plastic-adherent, multipotent cell population harvested from adipose tissue. The cell population is characterized by positive expression of CD44, CD73 and CD90 by at least 95% of the cells, positive expression of CD105 by at least 90% of the cells, and negative expression of CD45, CD19, CD11b and HLA-DR by at least 95% of the cells.

In some embodiments, the cell population is characterized by positive expression of CD44, CD73 and CD90 by at least 98% of the cells, positive expression of CD105 by at least 90% of the cells, and negative expression of CD45, CD19, CD11b and HLA-DR by at least 98% of the cells.

The cell population is further characterized by positive expression of CD34 by up to 10%-20% of the cells. In some embodiments, the cell population is characterized by positive expression of CD34 by up to 5% of the cells.

In some embodiments, at least 50% of the cells are positive for CD105, CD73, CD44 and CD90, and negative for CD45, CD19, CD11b and HLA-DR.

According to some embodiments, 90-100% of the human ADSCs are positive for the markers: CD44, CD73 and CD90. According to additional embodiments, at least 95% of the human ADSCs are positive for the markers: CD44, CD73 and CD90. According to yet additional embodiments, at least 98% of the human ADSCs are positive for the markers: CD44, CD73 and CD90.

According to some embodiments, 65-100% of the human ADSCs are positive for CD105. According to additional embodiments, 80-100% of the hADSCs are positive for CD105. According to yet additional embodiments, 90-100% of the hADSCs are positive



for CD105. According to yet additional embodiments, 80-95% of the hADSCs are positive for CD105.

According to some embodiments, 0.1-20% of the human ADSCs express the marker CD34. According to additional embodiments, 0.1-10% of the human ADSCs  
5 express the marker CD34.

According to other embodiments, 1-10% of the hADSCs are positive for the marker CD34. According to other embodiments, 1-5% of the hADSCs are positive for the marker CD34. According to some embodiments, at least 90% of the cells, for example at least 95% of the cells, are negative for the marker CD34.

10 According to some embodiments, at least 90% of the administered human ADSCs are negative for the markers: CD45, CD19, CD11b and HLA-DR. According to additional embodiments, at least 95% of the administered human ADSCs are negative for the markers: CD45, CD19, CD11b and HLA-DR. According to yet additional embodiments, at least 98% of the administered human ADSCs are negative for the markers: CD45,  
15 CD19, CD11b and HLA-DR.

According to some embodiments, at least 50% of the injected human ADSCs are positive for CD105, CD73, CD44 and CD90, and negative for CD45, CD19, CD11b, and HLA-DR. According to additional embodiments, at least 60%, 70%, 80% or 90% of the injected human ADSCs are positive for CD105, CD73, CD44 and CD90, and negative for  
20 CD45, CD19, CD11b and HLA-DR. Each possibility represents a separate embodiment of the invention.

Characterization of cell surface marker expression can be performed by methods known in the art, for example using fluorescence-activated cell sorting (FACS). FACS protocols for FACS are reviewed, for example, in: Flow Cytometry Protocols, Methods in  
25 Molecular Biology Volume 699 2011, Editors: Teresa S. Hawley, Robert G. Hawley Humana Press. Exemplary procedures are described below.

Adipose tissue as a source for multipotent stromal/stem cells has several advantages over other sources (Baer PC, Geiger H. *Stem Cells Int* 2012; 2012: 812693). For example, subcutaneous fat is omnipresent in humans and is easily accessible in large  
30 quantities by liposuction aspiration. Liposuction is a well-tolerated procedure yielding large quantities of tissue aspirate. The lipoaspirate is typically discarded as medical waste, qualifying it as a good starting material for adipose-derived stromal/stem cell (ASC)

isolation. The tissue contains a large number of multipotent cells which can be isolated and proliferated in culture.

According to some embodiments, the ADSCs are derived from human subcutaneous fat. According to particular embodiments, the cells are derived from human subcutaneous fat obtained by liposuction aspiration. The ADSCs may be obtained by liposuction procedures in various areas of the body including stomach, hips, thighs, arms, neck and buttocks. Any procedure of liposuction may be used according to the present invention for obtaining ADSCs, including but not limited to laser, ultrasound and fat removal by abdominoplasty, as known in the art.

The adipose tissue is processed to isolate the adipose-derived stem cells. Preparation methods typically include steps of washing the tissue with buffers such as PBS and saline, and/or with growth media (typically without any additives such as external cytokines or growth factors) e.g. DMEM, StemMACS<sup>TM</sup> or Plasma-Lyte, and treating the tissue with a tissue-dissociation enzyme such as collagenase and/or subjecting the tissue to non-enzymatic mechanical disruption, for example, using devices such as Tulip Nano Transfer<sup>TM</sup>. Enzymatic digestion of the sample can also be performed using a combination of dispase and collagenase. Liposomes, which are generally aggregated, can be separated from free stromal cells which include the stem cells and other cells such as red blood cells, endothelial cells, and fibroblast cells, by centrifugation. Erythrocytes may be lysed from the suspended pellet using a suitable lysis buffer and the remaining cells can be filtered or centrifuged.

As disclosed herein, an improved method for isolating the adipose-derived stem cells comprises freezing and thawing the adipose tissue prior to further processing. Advantageously, following thawing, the tissue can be processed to isolate the stem cells without the need to apply a lysis buffer to destroy the red blood cells. A standard lysis buffer is typically a solution of ammonium chloride (NH<sub>4</sub>Cl), potassium bicarbonate (KHCO<sub>3</sub>) and EDTA at pH 7.3. Such buffer composition selectively lyses red blood cells by exploiting specific characteristics of these cells and their limited ability to withstand osmotic stress.

Freezing according to some embodiments is performed as follows: a lipoaspirate is placed in a freezing bag and DMSO is added at a final concentration of 10%. The freezing bag is placed in a freezing canister and the sample is kept at -80<sup>0</sup>C overnight (~ 24 hours).



The frozen sample is then transferred to a vapor phase liquid nitrogen tank. Stability tests can be performed during the storage period.

For thawing, according to some embodiments, the sample is taken out and left at room temperature for a few minutes, typically 5-10 minutes. The sample is then thawed in  
5 a water bath at 37<sup>0</sup>C for a few minutes, typically between 5-10 minutes, or until most of the sample is thawed. The sample is then washed with a suspension medium capable of supporting cell viability, defined herein as an isotonic buffer or culture medium suitable for mesenchymal stem cells, for example, a buffer, such as PBS, at 37<sup>0</sup>C. The sample is typically washed twice.

10 In some embodiments, the process comprises conducting at least one filtration. Filtration is performed, in some embodiments, through a 100 micron mesh and subsequently through a 40 micron mesh in order to further dissociate the tissue and facilitate collection of the SVF fraction.

In order to isolate the ADSCs from within the population of cells in the SVF  
15 fraction, processes such as selection by adherence to a cell culture vessel (e.g. by plastic adherence) and/or via beads/antibodies are typically applied. Optionally, cells may be separated by cell sorting or separated immunohistochemically. Bunnell et al. (2008) *Methods.*, 45(2): 115–120, review methods for isolation of ADSCs.

Selection by adherence to the culture vessel is typically carried out by: seeding the  
20 SVF cells in a culture flask (e.g. plastic flask) with a suitable culture medium; incubating the seeded cells overnight (in some embodiments for at least 12 hours, or between 24-48 hours); washing the flask to remove non-adherent cells and tissue debris; and adding fresh culture medium to the flask. The adherent cells (ADSCs) may be cultured to a desired level of confluency, following which they may be collected and stored or sub-cultured to  
25 further passages.

In some embodiments, the hADSCs are hADSCs obtained from human subcutaneous fat by: (a) freezing a lipoaspirate; (b) thawing the lipoaspirate and dissociating with a tissue-dissociation enzyme or by mechanical disruption; (c) pelleting a cellular fraction comprising the hADSCs by centrifugation, and optionally washing the  
30 pellet with a suspension medium capable of supporting cell viability and subjecting the suspension to at least one additional centrifugation; (d) resuspending the pellet obtained in step (c) in a suspension medium capable of supporting cell viability and selecting plastic adherent hADSCs by overnight incubation in plastic flasks; (e) optionally conducting at

least one filtration to isolate the hADSCs prior to the plastic adherence selection; and (f) optionally culturing the hADSCs for at least 3 passages.

In some embodiments, the hADSCs are hADSCs obtained from human subcutaneous fat by: (a) freezing a lipoaspirate; (b) thawing the lipoaspirate and digesting  
5 with a collagenase; (c) pelleting a cellular fraction comprising the hADSCs by centrifugation and optionally washing the pellet with a buffer or culture medium and subjecting to a further centrifugation; (d) resuspending the pellet obtained in step (c) in a suitable culture medium; and selecting hADSCs by adherence to the cell culture vessel.

In some embodiments, the method for obtaining hADSCs from human  
10 subcutaneous fat for administration to a subject in need thereof consists essentially of:

(a) freezing a lipoaspirate;

(b) thawing the lipoaspirate and dissociating with a tissue-dissociation enzyme or by mechanical disruption;

(c) pelleting a cellular fraction comprising the hADSCs by centrifugation, and  
15 optionally washing the pellet with a suspension medium capable of supporting cell viability and subjecting the suspension to at least one additional centrifugation;

(d) resuspending the pellet obtained in step (c) in a suspension medium capable of supporting cell viability and conducting at least one filtration;

(e) selecting hADSCs by adherence to the cell culture vessel; and

20 (f) optionally culturing the hADSCs for at least 3 passages prior to their administration to the subject.

An exemplary procedure for isolating ADSCs is described in Example 1 below.

In some preferred embodiments, the ADSCs are cultured before being provided to a subject in need thereof (and/or before being stored for later use). Preferably, the cells are  
25 cultured in a xeno-free medium. In some embodiments, the ADSCs are grown to about 80%-100% confluency for example to about 80% confluency, and sub-cultured to a passage number between 3-10, preferably between 3-5 or 3-4, before administration to the subject. Thus, in some embodiments, the administered cells are at a passage between 3 to 10. In additional embodiments, the administered cells are at passage number between 3 to  
30 5. In some embodiments, the ADSCs are sub-cultured to passage number 3. In some embodiments, the ADSCs are sub-cultured to passage number 4. In some embodiments, the ADSCs are sub-cultured to passage number 5.



Before administration, cells are counted and prepared for injection in a pharmaceutically acceptable diluent/carrier. Typically, the cells are concentrated before administration to the subject. The concentration typically ranges from  $1.5 \times 10^4/\text{ml}$  to  $100 \times 10^6/\text{ml}$ .

5 A stem cell composition for single administration according to the methods of the present invention comprises, in some embodiments,  $10^5 - 3 \times 10^8$  human ADSCs. According to some embodiments, the composition comprises  $10^5 - 10^8$  human ADSCs. According to additional embodiments,  $10^6 - 10^7$  human ADSCs are injected in one administration. According to yet additional embodiments,  $200 \times 10^6 - 300 \times 10^6$  human  
10 ADSCs are injected in one administration. According to yet additional embodiments,  $10^7 - 2 \times 10^8$  human ADSCs are injected in one administration.

According to some embodiments, the ADSC composition of the present invention is for use by systemic administration. Typically, the administration is into the central nervous system (CNS) of a subject. Such administration may be aimed at bypassing the  
15 blood brain barrier. According to yet other embodiments, the ADSCs are administered directly to a specific region of the brain.

According to some embodiments, the composition is administered to the CNS, for example, by intraspinal administration. According to some embodiments, the composition is administered intrathecally. According to other embodiments, the composition is  
20 administered by intraventricular or intracerebroventricular (ICV) route, namely into the brain ventricles.

Intraventricular drug delivery is the delivery of medication within the cerebrospinal fluid of the cistern (C1-2 vertebra) and intracranial ventricles. By administering medication directly, less medication is needed, and fewer side effects are  
25 seen than with orally administered drugs. The medicine is typically delivered through an implanted catheter connected to a pump, as known in the art. The pump may be programmable, and either implanted or external.

Intrathecal administration is a route of administration for drugs via an injection into the spinal canal, more specifically into the subarachnoid space so that it reaches the  
30 cerebrospinal fluid (CSF) and is useful in spinal anesthesia, chemotherapy, or pain management applications. This route is also used to introduce drugs that fight certain infections, particularly post-neurosurgical. The drug needs to be given this way to avoid the blood brain barrier. Intrathecal and epidural drug delivery comprise the intraspinal

routes of drug administration. Each route delivers drug to the cerebrospinal fluid (CSF). Intrathecal delivery involves the direct injection of the drug into the CSF within the intrathecal space of the spinal column, whereas drugs injected in the epidural space have to cross the dura membrane in order to reach the CSF. As such, epidurally administered drugs can also reach the systemic circulation whereas intrathecally administered drugs are confined within the CSF circulating in the spinal column and the brain ventricles.

Also encompassed by the present invention is a combination therapy of adipose-derived stem cells and optionally at least one other active agent.

Active agents within the scope of the present invention include, but are not limited to interferons, e.g. pegylated or non-pegylated  $\alpha$ -interferons, or  $\beta$ -interferons, e.g. interferon  $\beta$ -1a or interferon  $\beta$ -1b, or  $\tau$ -interferons; immunosuppressants with optionally antiproliferative/antineoplastic activity, e.g. mitoxantrone, methotrexate, azathioprine, cyclophosphamide, or steroids, e.g. methylprednisolone, prednisone or dexamethasone, or steroid-secreting agents, e.g. ACTH; adenosine deaminase inhibitors, e.g. cladribine; IV immunoglobulin G (e.g. as disclosed in Neurology, 1998, May 50(5):1273-81) monoclonal antibodies to various T-cell surface markers, e.g. natalizumab (ANTEGREN®) or alemtuzumab; TH2 promoting cytokines, e.g. IL-4, IL-10, or compounds which inhibit expression of TH1 promoting cytokines, e.g. phosphodiesterase inhibitors, e.g. pentoxifylline; antispasticity agents including baclofen, diazepam, piracetam, dantrolene, lamotrigine, rifluzole, tizanidine, clonidine, beta blockers, cyproheptadine, orphenadrine or cannabinoids; AMPA glutamate receptor antagonists, e.g. 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, [1,2,3,4,-tetrahydro-7-morpholin-yl-2,3-dioxo-6-(trifluoromethyl)quinoxalin-yl]methylphosphonate, 1-(4-aminophenyl)-4-methyl-7,8-methylene-dioxy-5H-2,3-benzodiazepine, or (-)-1-(4-aminophenyl)-4-methyl-7,8-methylene-dioxy-4,5-dihydro-3-methylcarbamoyl-2,3-benzodiazepine; inhibitors of VCAM-1 expression or antagonists of its ligand, e.g. antagonists of the  $\alpha 4 \beta 1$  integrin VLA-4 and/or  $\alpha 4 \beta 7$  integrins, e.g. natalizumab (ANTEGREN®); anti-macrophage migration inhibitory factor (Anti-MIF); xii) Cathepsin S inhibitors; xiii) mTor inhibitors. Each possibility represents a separate embodiment of the invention. Currently preferred one other active agent is FTY720 (2-amino-2-[2-(4-octylphenyl) ethyl] propane-1, 3-diol; fingolimod) belonging to the class of immunosuppressants.



The invention encompasses the combination of ADSCs, with at least one additional drug, preferably, an immunosuppressant, particularly fingolimod.

The present invention also provides use in the treatment of multiple sclerosis of human ADSCs, optionally together with an additional drug being suitable for the treatment of multiple sclerosis.

The following examples are presented in order to more fully illustrate certain embodiments of the invention. They should in no way, however, be construed as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.

## EXAMPLES

### **Example 1 - Effect of human adipose derived stem cells (hADSCs) on MOG-induced chronic EAE in C57BL/6 mice**

#### **Materials and Methods**

##### **ADSCs isolation:**

Lipoaspirate obtained from human healthy donors was frozen at  $-80^{\circ}\text{C}$  and then in vapor phase liquid nitrogen (for over a week). The lipoaspirate was then thawed and washed twice with an equal volume of PBS at  $37^{\circ}\text{C}$ . The lipoaspirate was then digested with collagenase (NB4, Serva) at  $37^{\circ}\text{C}$  for 35 minutes with shaking. An equivalent volume of DMEM was added and the sample span down once at RT, 300-500g, for 10 min. The precipitated fraction was washed with DMEM, span down again and the pellet resuspended in culture medium (StemMACS<sup>TM</sup>, Miltenyi), without applying red blood cells lysis buffer. The amount of culture medium was calculated as follows: 50ml for every 150ml of initial lipoaspirated tissue. The sample was then filtered through a  $100\mu\text{m}$  filter, followed by the addition of additional 5ml medium and centrifugation at 500g for 10 minutes at RT. The procedure was repeated with a  $40\mu\text{m}$  filter and the cells were counted. The resulting cells are referred as stromal vascular fraction (SVF).

##### **Cell culture:**

The SVF fraction was plated at a density of  $\sim 2 \times 10^6$  cells per  $75\text{ cm}^2$  without any coating and incubated overnight to select for plastic adherent cells (ADSCs). The next day the flask was washed to remove non-adherent cells and tissue debris, fresh medium was

added, and the cells were grown to 80-100% confluency, trypsinized and sub-cultured up to passage 3-5.

Cells were then collected and analyzed for the markers: CD105, CD73, CD90, CD45, CD44, CD19, CD11b, HLA-DR and CD34. The cells were stored frozen in liquid  
5 nitrogen until use. For use, frozen cells were thawed and plated at a concentration of 5000cells/cm<sup>2</sup> and incubated overnight.

Prior to cells ICV injection the cells were trypsinized, counted and prepared for injection at the selected concentration detailed in **Table 2** below and kept on ice until use for a period no longer than 30min. ICV injection was performed using a stereotactic  
10 system and care was taken not to injure the mice brain.

Animals: All animal studies were approved by local ethics committees. C57BL/6 female mice, 7-9 weeks old were randomized into control or treatment groups with similar mean weight. Animals were given food and water *ad libitum* throughout the experiment.

Induction of Experimental Autoimmune Encephalomyelitis (EAE): In order to  
15 induce EAE, an emulsion of myelin-oligodendrocyte-glycoprotein (MOG) 35-55 (GL Biochem co. Ltd, Shanghai, China) in modified Complete Freund's Adjuvant (CFA) (Sigma-Aldrich, St. Louis, MO, USA) was prepared as follows: heat-killed *M. tuberculosis* strain H37RA (Sigma) was added to CFA reaching a final concentration of 4mg/mL. Subsequently, 2mg/mL MOG 35-55 were emulsified with an equal amount of  
20 modified CFA. EAE had been induced by injection of this emulsion subcutaneously (SC) on the shaved back of the mouse at one site, followed by an intraperitoneal injection of *Bordetella pertussis* toxin (Sigma) in PBS on Day 0, and 48 hours post MOG immunization.

#### Measurements:

25 Body weight was measured daily from Day 0 to Day 29. EAE was assessed by clinical scoring of the mice once daily from Day 0 to Day 29 post-immunization (**Table 1**). Dead animals (if occur) received a clinical score of 5 and the last weight measurement before animal death was recorded as final weight.



Table 1: EAE Clinical Score

| Score | Clinical Signs                                   |
|-------|--|
| 0     | Normal mouse; no overt signs of disease          |
| 1     | Limp tail  |
| 2     | Hind limb paralysis                              |
| 3     | Hind and front limb paralysis                    |
| 4     | Complete paralysis: sacrifice for humane reasons |
| 5     | Moribund state; Death by EAE                     |

The following calculations were derived from clinical score raw data:

Mean maximum score:

5 is the mean of the highest scores noted for each mouse in a specific group up to an indicated day of analysis.

Mean disease duration:

$$\frac{\text{sum of (day of analysis – day of disease onset for each mouse)}}{\text{(number of mice per group)}}$$

10

Mean day of onset:

$$\frac{\text{sum of day of disease onset of each mouse}}{\text{number of mice per group}}$$

15

Area under the curve (AUC) of clinical score:  
calculated using Microsoft Excel and represents disease burden.

Experimental design:

20 The experimental design of the EAE model is detailed in **Table 2** (n=10 in each group).

25

Table 2: Experimental design

| Group (test article)   | Route | Cell Dose (number of cells) | Days of administration | Vehicle, injection volume |
|------------------------|-------|-----------------------------|------------------------|---------------------------|
| Control/ Vehicle (PBS) | ICV   | 0                           | 0                      | PBS 4 ul                  |
| ADSCs 100K             | ICV   | 1x10 <sup>5</sup>           | 0                      | PBS 4 ul                  |
| ADSCs 200K             | ICV   | 2x10 <sup>5</sup>           | 0                      | PBS 4 ul                  |
| ADSCs 400K             | ICV   | 4x10 <sup>5</sup>           | 0                      | PBS 4 ul                  |

Statistical analysis: Each data set was analyzed using single-factor analysis of variance (ANOVA) followed by two-tailed, two-sample students' T test assuming unequal  
5 variances, n=10 / group, +/- standard error.

**Results**

The results of the trial, calculated up to 28 days from the first injection of the test articles, are described in **Table 3** and **Figures 1-6**.

10 Phenotype of the cells:

| Marker (dye)  | % expression |
|---------------|--------------|
| CD73 (PE*)    | 100          |
| CD90 (PE)     | 100          |
| CD105 (PE)    | 100          |
| CD44 (FITC**) | 100          |
| HLA-DR (PE)   | 0.1          |
| CD34 (PE)     | 1.5          |
| CD45 (PE)     | 0.5          |
| CD11b (PE)    | 0.2          |
| CD19 (PE)     | 0.1          |
| IgG1 (PE)     | 0.2          |
| IgG2a (PE)    | 0.1          |
| IgG1 (FITC)   | 0            |



Table 3: Effect of ADSCs on EAE

| Groups                   | AUC Clinical Score | Maximum Mean Disease Score | Mean Day of Onset | Survival Rate at Day 28 |
|--------------------------|--------------------|----------------------------|-------------------|-------------------------|
| Control/<br>Vehicle(PBS) | 36.05±3.33         | 2.90±0.19                  | 11.30±0.42        | 100%                    |
| ADSCs 100K               | 33.45±2.78         | 3.00±0.20                  | 12.40±0.54        | 100%                    |
| ADSCs 200K               | 26.95±3.13         | 2.35±0.18                  | 12.70±0.80        | 100%                    |
| ADSCs 400K               | 29.38±1.12         | 2.6±0.10                   | 12.50±0.43        | 100%                    |

5 The ICV transplantation of ADSCs in an EAE MOG model showed a decrease in the rate of appearance of the symptoms of the disease at all of the three dosages studied (**Figure 1**). The most effective dose was  $2 \times 10^5$  cells/animal that showed a significant reduction in the severity of the disease, reaching a plateau at a Mean Clinical Score of  $2 \pm 0.11$ , as compared to  $2.75 \pm 0.25$  for the vehicle group (**Figure 2**). One –hundred  
10 thousand ( $1 \times 10^5$ ) cells per mice did not seem to be enough to elicit changes in progression of the disease and the behavior of the animals was similar to the vehicle control group. As is observed in **Figure 3**, the highest dose ( $4 \times 10^5$  cells/animal), although effective in the reduction of the symptoms, is less effective than the middle dose of  $2 \times 10^5$  cell/animal, probably due to a high density of the cells in the small ICV space of mice.

15 Analysis of the body weight of the animals confirmed the observation noted in the analysis of the clinical score of the animals. The two higher dosages of the cells ( $2 \times 10^5$  and  $4 \times 10^5$  cells/animal) resulted in a higher average body weight, which was preserved throughout the experiment (**Figure 4**).

20 The area under the curve (AUC) of Mean Clinical Score calculated as a function of cell dose at day 28 post immunization was significantly lower for the  $2 \times 10^5$  ADSCs and  $4 \times 10^5$  ADSCs animal groups compared to the vehicle and to  $1 \times 10^5$  ADSC (**Figure 5**). Furthermore, the Mean Maximal Disease Score in the  $2 \times 10^5$  ADSCs group at day 28 post immunization was significantly lower than that of the  $1 \times 10^5$  ADSCs and the control group (**Figure 6**).

25 The experimental data show a clear advantage of the ICV transplantation of ADSC with a maximum effect at  $2 \times 10^5$  cells per mice. This ADSC dose yielded a long term

effect on the attenuation of EAE symptoms that led to a significant reduction of disease burden.

**Example 2- Analyses of cell surface markers of ADSCs**

5           **Tables 4-12** summarize FACS analyses of nine (9) samples of ADSCs prepared as described in Example 1 above, following 1-5 passages. **Tables 13-14** and **Figure 7** show the average and standard deviation (“StDev”) values. As can be seen in the tables and figure, the markers are stabilized after P3. Passage numbers P3-P4 are equivalent to no more than approximately 14 population doublings.

10

Table 4

|          | Marker (dye)  | Passage |      |      |      |      |      |           |
|----------|---------------|---------|------|------|------|------|------|-----------|
|          |               | 0       | 1    | 2    | 3    | 4    | 5    |           |
| Sample 1 | CD73 (PE*)    | 99.1    | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 | Positives |
|          | CD90 (PE)     | 97      | 99.9 | 99.9 | 99.9 | 99.9 | 100  |           |
|          | CD105 (PE)    | 90.4    | 78.3 | 97.8 | 89   | 82.1 | 99.7 |           |
|          | CD44 (FITC**) | 99.6    | 99.8 | 99.9 | 99.9 | 99.7 | 99.8 |           |
|          | HLA-DR (PE)   | 1.2     | 0.2  | 0.1  | 0.1  | 0.4  | 0.1  | Negatives |
|          | CD34 (PE)     | 14.6    | 0.3  | 0.2  | 0.2  | 1.2  | 10.8 |           |
|          | CD45 (PE)     | 1.5     | 0.1  | 0.1  | 0    | 0.1  | 0.4  |           |
|          | CD11b (PE)    | 1.6     | 0.1  | 0    | 0    | 0    | 0    |           |
|          | CD19 (PE)     | 0.3     | 0.1  | 0    | 0    | 0    | 0.2  |           |
|          | IgG1 (PE)     | 0.3     | 0    | 0.1  | 0    | 0.1  | 0    | Controls  |
|          | IgG2a (PE)    | 0.3     | 0.1  | 0.1  | 0    | 0    | 0    |           |
|          | IgG1 (FITC)   | 0.3     | 0    | 0    | 0    | 0    | 0.1  |           |

\*PE- Phycoerythrin  
\*\* FITC- Fluorescein isothiocyanate



Table 5

|          | Marker (dye) | Passage |      |      |      |      |      |           |
|----------|--------------|---------|------|------|------|------|------|-----------|
|          |              | 0       | 1    | 2    | 3    | 4    | 5    |           |
| Sample 2 | CD73 (PE)    | 99.9    | 100  | 100  | 100  | 100  | 100  | Positives |
|          | CD90 (PE)    | No data | 100  | 99.9 | 100  | 99.9 | 100  |           |
|          | CD105 (PE)   | 79.5    | 76.3 | 98.8 | 98.1 | 99.6 | 97.3 |           |
|          | CD44 (FITC)  | 99.2    | 99.2 | 99.9 | 99.4 | 99.7 | 99.4 |           |
|          | HLA-DR (PE)  | 0.3     | 0.1  | 0.1  | 0    | 0.1  | 0.2  | Negatives |
|          | CD34 (PE)    | 0.4     | 0.3  | 0.4  | 1.4  | 3.1  | 5    |           |
|          | CD45 (PE)    | 0.2     | 0    | 0.1  | 0.1  | 0.1  | 0.4  |           |
|          | CD11b (PE)   | 0.1     | 0    | 0    | 0    | 0    | 0.1  |           |
|          | CD19 (PE)    | 0.1     | 0    | 0    | 0    | 0.1  | 0.4  |           |
|          | IgG1 (PE)    | 0.1     | 0.1  | 0    | 0    | 0    | 0.1  | Controls  |
|          | IgG2a (PE)   | 0.1     | 0.1  | 0    | 0.1  | 0    | 0    |           |
|          | IgG1 (FITC)  | 1       | 0    | 0    | 0    | 0    | 0    |           |

Table 6

|          | Marker (dye) | Passage |      |      |      |      |      |           |
|----------|--------------|---------|------|------|------|------|------|-----------|
|          |              | 0       | 1    | 2    | 3    | 4    | 5    |           |
| Sample 3 | CD73 (PE)    | 99.8    | 100  | 100  | 100  | 100  | 100  | Positives |
|          | CD90 (PE)    | 99.9    | 100  | 99.9 | 99.9 | 100  | 100  |           |
|          | CD105-PE     | 90.8    | 99.9 | 98.3 | 99.4 | 99.3 | 86.9 |           |
|          | CD44 (FITC)  | 99.4    | 99.9 | 99.8 | 99.5 | 99.6 | 95.9 |           |
|          | HLA-DR (PE)  | 0.7     | 0.1  | 0    | 0    | 0.1  | 0.1  | Negatives |
|          | CD34 (PE)    | 21.4    | 5    | 1.4  | 6.8  | 7    | 2.3  |           |
|          | CD45 (PE)    | 0.5     | 20.4 | 0.1  | 0.1  | 2.2  | 1.2  |           |
|          | CD11b (PE)   | 0.2     | 0.2  | 0    | 0    | 0.2  | 0    |           |
|          | CD19 (PE)    | 0.2     | 0.3  | 0    | 0    | 0.1  | 0.1  |           |
|          | IgG1 (PE)    | 0.2     | 0.1  | 0    | 0    | 0.1  | 0    | Controls  |
|          | IgG2a (PE)   | 0.2     | 0.1  | 0    | 0    | 0.1  | 0    |           |
|          | IgG1 (FITC)  | 0.1     | 0    | 0    | 0.1  | 0    | 0    |           |

Table 7

|          | Marker (dye) | Passage |      |      |      |      |      |           |
|----------|--------------|---------|------|------|------|------|------|-----------|
|          |              | 0       | 1    | 2    | 3    | 4    | 5    |           |
| Sample 4 | CD73 (PE)    | 99.9    | 99.9 | 99.9 | 100  | 99.9 | 99.9 | Positives |
|          | CD90 (PE)    | 99.9    | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 |           |
|          | CD105 (PE)   | 99.4    | 96.9 | 99.1 | 99.6 | 99.9 | 99.9 |           |
|          | CD44 (FITC)  | 99.3    | 98   | 99.5 | 99.5 | 99.4 | 99.8 |           |
|          | HLA-DR (PE)  | 0.2     | 0    | 0.2  | 0    | 0.1  | 0.4  | Negatives |
|          | CD34 (PE)    | 13.6    | 4.8  | 3.3  | 23.1 | 4    | 1.9  |           |
|          | CD45 (PE)    | 0.7     | 0.1  | 0.2  | 9.7  | 0.3  | 0.2  |           |
|          | CD11b (PE)   | 0.2     | 0    | 0    | 0.1  | 0.4  | 0.2  |           |
|          | CD19 (PE)    | 0.8     | 0    | 0.1  | 5.7  | 0.5  | 3.5  |           |
|          | IgG1 (PE)    | 0.1     | 0    | 0    | 0.1  | 0.1  | 0    | Controls  |
|          | IgG2a (PE)   | 0.2     | 0    | 0.1  | 0    | 0    | 0    |           |
|          | IgG1 (FITC)  | 0.1     | 0    | 0.1  | 0    | 0    | 0    |           |

Table 8

|          | Marker (dye) | Passage |      |      |      |      |      |           |
|----------|--------------|---------|------|------|------|------|------|-----------|
|          |              | 0       | 1    | 2    | 3    | 4    | 5    |           |
| Sample 5 | CD73 (PE)    | 99.9    | 100  | 99.8 | 99.9 | 99.9 | 100  | Positives |
|          | CD90 (PE)    | 99.9    | 100  | 100  | 99.9 | 99.9 | 100  |           |
|          | CD105 (PE)   | 98.7    | 99.9 | 91.3 | 99.9 | 99.9 | 99.7 |           |
|          | CD44 (FITC)  | 98.8    | 99.9 | 97.4 | 99.8 | 100  | 99.9 |           |
|          | HLA-DR (PE)  | 0.4     | 0.1  | 0.2  | 0.1  | 0.1  | 0.1  | Negatives |
|          | CD34 (PE)    | 16.7    | 0.2  | 1.1  | 1.4  | 3.7  | 17.6 |           |
|          | CD45 (PE)    | 3.4     | 0    | 0.2  | 1.6  | 0.8  | 0.3  |           |
|          | CD11b (PE)   | 0.4     | 0.1  | 0.6  | 0    | 0    | 0.1  |           |
|          | CD19 (PE)    | 0.3     | 0.1  | 0.1  | 0.2  | 0    | 0.5  |           |
|          | IgG1 (PE)    | 0.3     | 0    | 0    | 0    | 0    | 0    | Controls  |
|          | IgG2a (PE)   | 0.4     | 0    | 0.1  | 0    | 0    | 0.1  |           |
|          | IgG1 (FITC)  | 0.2     | 0    | 0    | 0    | 0    | 0    |           |



Table 9

|          | Marker (dye) | Passage |      |      |      |      |      |           |
|----------|--------------|---------|------|------|------|------|------|-----------|
|          |              | 0       | 1    | 2    | 3    | 4    | 5    |           |
| Sample 6 | CD73 (PE)    | No data | 99.3 | 99.9 | 99.9 | 99.9 | 100  | Positives |
|          | CD90 (PE)    | No data | 100  | 100  | 100  | 99.9 | 100  |           |
|          | CD105 (PE)   | No data | 61.7 | 29.7 | 75.1 | 74.4 | 96.2 |           |
|          | CD44 (FITC)  | No data | 94.5 | 98.4 | 98.9 | 99.7 | 99.8 |           |
|          | HLA-DR (PE)  | No data | 0.1  | 0    | 0.1  | 0.1  | 0.1  | Negatives |
|          | CD34 (PE)    | No data | 9.5  | 1    | 2.4  | 5.5  | 9.7  |           |
|          | CD45 (PE)    | No data | 1.7  | 0.5  | 0.9  | 0.8  | 2.4  |           |
|          | CD11b (PE)   | No data | 0    | 0.1  | 0    | 0    | 0.7  |           |
|          | CD19 (PE)    | No data | 0.1  | 0    | 0.4  | 0.3  | 2.3  |           |
|          | IgG1 (PE)    | No data | 0.1  | 0    | 0.1  | 0.1  | 0.3  | Controls  |
|          | IgG2a (PE)   | No data | 0.2  | 0.2  | 0.1  | 0.1  | 0.2  |           |
|          | IgG1 (FITC)  | No data | 0    | 0    | 0    | 0    | 0    |           |

Table 10

|          | Marker (dye) | Passage |      |      |      |      |      |           |
|----------|--------------|---------|------|------|------|------|------|-----------|
|          |              | 0       | 1    | 2    | 3    | 4    | 5    |           |
| Sample 7 | CD73 (PE)    | 99.9    | 100  | 100  | 99.9 | 100  | 99.9 | Positives |
|          | CD90 (PE)    | 99.9    | 100  | 100  | 99.9 | 99.1 | 100  |           |
|          | CD105 (PE)   | 99.7    | 99.9 | 99.5 | 99.9 | 99.1 | 100  |           |
|          | CD44 (FITC)  | 99.9    | 100  | 99.8 | 99.7 | 99.8 | 99.9 |           |
|          | HLA-DR (PE)  | 0.3     | 0.2  | 0.2  | 0.2  | 0.1  | 0.1  | Negatives |
|          | CD34 (PE)    | 12      | 0.9  | 10.1 | 0.4  | 3.6  | 0.7  |           |
|          | CD45 (PE)    | 0.9     | 0.5  | 2.1  | 0.2  | 0.2  | 0.3  |           |
|          | CD11b (PE)   | 0.1     | 0.1  | 0.6  | 0.1  | 0.1  | 0.1  |           |
|          | CD19 (PE)    | 0.7     | 0.2  | 0.2  | 0.2  | 0.4  | 0.1  |           |
|          | IgG1 (PE)    | 0.2     | 0.1  | 0.2  | 0.2  | 0.2  | 0.1  | Controls  |
|          | IgG2a (PE)   | 0.3     | 0.2  | 0.1  | 0.1  | 0.1  | 0.1  |           |
|          | IgG1 (FITC)  | 0.2     | 0    | 0.1  | 0    | 0.1  | 0.1  |           |

Table 11

|          | Marker (dye) | Passage |      |      |      |      |      |           |
|----------|--------------|---------|------|------|------|------|------|-----------|
|          |              | 0       | 1    | 2    | 3    | 4    | 5    |           |
| Sample 8 | CD73 (PE)    | 99.7    | 100  | 99.7 | 99.8 | 99.7 | 99.9 | Positives |
|          | CD90 (PE)    | 99.5    | 99.8 | 99.8 | 99.8 | 99.7 | 99.9 |           |
|          | CD105 (PE)   | 94      | 99.9 | 99.7 | 92.9 | 95.9 | 89.7 |           |
|          | CD44 (FITC)  | 99.9    | 100  | 100  | 100  | 100  | 99.9 |           |
|          | HLA-DR (PE)  | 0.5     | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  | Negatives |
|          | CD34 (PE)    | 73      | 0.7  | 0.2  | 0.4  | 0.3  | 4.9  |           |
|          | CD45 (PE)    | 0.5     | 0.1  | 0.1  | 0.1  | 0.1  | 0.1  |           |
|          | CD11b (PE)   | 0.3     | 0    | 0    | 0    | 0    | 0    |           |
|          | CD19 (PE)    | 0.3     | 0    | 0    | 0    | 0    | 0.1  |           |
|          | IgG1 (PE)    | 0.2     | 0.2  | 0    | 0.2  | 0.1  | 0    | Controls  |
|          | IgG2a (PE)   | 0.3     | 0.1  | 0    | 0.1  | 0.1  | 0.1  |           |
|          | IgG1 (FITC)  | 0.2     | 0    | 0    | 0.1  | 0.1  | 0    |           |

5

Table 12

|          | Marker (dye) | Passage |      |      |      |      |      |           |
|----------|--------------|---------|------|------|------|------|------|-----------|
|          |              | 0       | 1    | 2    | 3    | 4    | 5    |           |
| Sample 9 | CD73 (PE)    | 99.9    | 100  | 99.9 | 100  | 99.9 | 100  | Positives |
|          | CD90 (PE)    | 99.9    | 99.9 | 99.9 | 99.5 | 99.9 | 100  |           |
|          | CD105 (PE)   | 99.7    | 100  | 99.7 | 99.7 | 99.9 | 99.8 |           |
|          | CD44 (FITC)  | 99.8    | 99.8 | 99.8 | 99.9 | 99.8 | 99.9 |           |
|          | HLA-DR (PE)  | 0.1     | 0    | 0.2  | 0.1  | 0.1  | 0.1  | Negatives |
|          | CD34 (PE)    | 4.1     | 2.3  | 0.1  | 3.2  | 1.2  | 2.1  |           |
|          | CD45 (PE)    | 0.1     | 0.2  | 0    | 0.1  | 0.4  | 0.3  |           |
|          | CD11b (PE)   | 0.1     | 0    | 0    | 0.1  | 0.1  | 0.1  |           |
|          | CD19 (PE)    | 0.2     | 0.1  | 0.1  | 0.3  | 0.1  | 0.1  |           |
|          | IgG1 (PE)    | 0.3     | 0.3  | 0.2  | 0.2  | 0.2  | 0.2  | Controls  |
|          | IgG2a (PE)   | 0.2     | 0.1  | 0.2  | 0.1  | 0.1  | 0.1  |           |
|          | IgG1(FITC)   | 0.1     | 0.1  | 0.1  | 0.1  | 0.1  | 0.2  |           |



Table 13 - average

|         | Marker (dye) | Passage |      |      |      |      |       |           |
|---------|--------------|---------|------|------|------|------|-------|-----------|
|         |              | 0       | 1    | 2    | 3    | 4    | 5     |           |
| Average | CD73 (PE)    | 99.8    | 99.9 | 99.9 | 99.9 | 99.9 | 100.0 | Positives |
|         | CD90 (PE)    | 99.4    | 99.9 | 99.9 | 99.9 | 99.8 | 100.0 |           |
|         | CD105 (PE)   | 94.0    | 90.3 | 90.4 | 94.8 | 94.5 | 96.6  |           |
|         | CD44 (FITC)  | 99.5    | 99.0 | 99.4 | 99.6 | 99.7 | 99.4  |           |
|         | HLA-DR (PE)  | 0.5     | 0.1  | 0.1  | 0.1  | 0.1  | 0.1   | Negatives |
|         | CD34 (PE)    | 19.5    | 2.7  | 2.0  | 4.4  | 3.3  | 6.1   |           |
|         | CD45 (PE)    | 1.0     | 2.6  | 0.4  | 1.4  | 0.6  | 0.6   |           |
|         | CD11b (PE)   | 0.4     | 0.1  | 0.1  | 0.0  | 0.1  | 0.1   |           |
|         | CD19 (PE)    | 0.4     | 0.1  | 0.1  | 0.8  | 0.2  | 0.8   |           |
|         | IgG1 (PE)    | 0.2     | 0.1  | 0.1  | 0.1  | 0.1  | 0.1   | Controls  |
|         | IgG2a (PE)   | 0.3     | 0.1  | 0.1  | 0.1  | 0.1  | 0.1   |           |
|         | IgG1 (FITC)  | 0.3     | 0.0  | 0.0  | 0.0  | 0.0  | 0.0   |           |

Table 14 - StDev

|       | Marker (dye) | Passage |      |      |     |     |     |           |
|-------|--------------|---------|------|------|-----|-----|-----|-----------|
|       |              | 0       | 1    | 2    | 3   | 4   | 5   |           |
| StDev | CD73 (PE)    | 0.3     | 0.2  | 0.1  | 0.1 | 0.1 | 0.1 | Positives |
|       | CD90 (PE)    | 1.1     | 0.1  | 0.1  | 0.2 | 0.3 | 0.0 |           |
|       | CD105 (PE)   | 7.1     | 14.4 | 22.9 | 8.3 | 9.5 | 4.9 |           |
|       | CD44 (FITC)  | 0.4     | 1.8  | 0.9  | 0.3 | 0.2 | 1.3 |           |
|       | HLA-DR (PE)  | 0.4     | 0.1  | 0.1  | 0.1 | 0.1 | 0.1 | Negatives |
|       | CD34 (PE)    | 22.6    | 3.2  | 3.2  | 7.3 | 2.2 | 5.6 |           |
|       | CD45 (PE)    | 1.1     | 6.7  | 0.7  | 3.1 | 0.7 | 0.7 |           |
|       | CD11b (PE)   | 0.5     | 0.1  | 0.3  | 0.1 | 0.1 | 0.2 |           |
|       | CD19 (PE)    | 0.3     | 0.1  | 0.1  | 1.9 | 0.2 | 1.2 |           |
|       | IgG1 (PE)    | 0.1     | 0.1  | 0.1  | 0.1 | 0.1 | 0.1 | Controls  |
|       | IgG2a (PE)   | 0.1     | 0.1  | 0.1  | 0.1 | 0.1 | 0.1 |           |
|       | IgG1(FITC)   | 0.3     | 0.0  | 0.1  | 0.1 | 0.1 | 0.1 |           |

5

**Example 3- SVF isolation with vs. without red blood cell lysis****Study design**

Two 150ml cryopreserved lipoaspirated tissue samples were taken from two different batches stored in vapor phase nitrogen (total of four lipoaspirated tissue samples). The tissue samples were thawed and SVFs were isolated from each sample as

will be detailed below. Each tissue sample was processed in the same manner prior to the red blood cell lysis buffer step. At that point, two samples (one from each batch) were subjected to the red blood cell lysis step using ACK lysis buffer (Lonza) (samples designated as “A”), while the other two samples (one from each batch) were not subjected to this step (samples designated as “B”). After the lysis step the SVF isolation process proceeded in the same manner for all samples.

Following SVF isolation cells were counted and the following parameters were measured:

- Viable cell number/ml
- Dead cell number/ml
- Total number of viable cells per sample
- Viability percent
- Average cell size(um)

Cells from each sample were then seeded and expanded to passage 0 (P0). For each batch, all flasks were harvested when one of the samples reached 70-80% confluency. At P0 the following parameters were measured:

- Viable cell number/ml
- Dead cell number/ml
- Total number of viable cells per sample
- Viability percent
- Average cell size (μm)
- MSC morphology
- Immunophenotype (FACS analysis: CD90, CD73, CD45 and CD31)
- Time to harvest (days)

## **Procedure**

### **Lipoaspirated tissue thawing and SVF isolation**

Two 150ml lipoaspirated tissue samples from two different batches, identified as batch EF137 and batch EF144, were thawed (total of four lipoaspirated tissue samples). Each thawed tissue sample was transferred into a 500ml centrifuge tube. For each batch, one tube was labeled as “A” and the other as “B”. A 150ml collagenase solution (142ml PBS, 7.5ml of 5% collagenase stock solution, 0.6ml CaCl<sub>2</sub> 1M) was added to each tube and the tubes were incubated at 37°C in a water bath for approximately half an hour with



shaking (130 rpm). Next, 200ml of DMEM Low Glucose (DMEM LG, Gibco) were added to each tube at room temperature and the tubes were centrifuged for 10 min at 500x g, 21±2°C. At the end of the centrifugation most of the supernatant was removed, leaving approximately 5 ml. The pellet in each tube was resuspended in the remaining supernatant and transferred into a 50ml conical tube. Next, 45ml of DMEM LG were added to each 50ml tube and the tubes were centrifuged for 10 min at 500x g, 21±2°C. Following this second centrifugation the supernatant was removed and the pellet in the tubes designated as “B” was resuspended in 5ml of DMEM LG.

For tubes designated as “A”, the pellet was resuspended in 10ml of ACK red blood cell lysis buffer and incubated for approximately 10 min at 15-25°C. Next, 20ml of PBS (15-25°C) were added to the tube and the tube was centrifuged for 10min at 500x g, 21±2°C. Following centrifugation, the supernatant was removed and the pellet was resuspended in 5ml of DMEM LG.

Both tubes designated A and tubes designated B were then subjected to two filtration steps in a similar manner: a 100µm mesh filter was placed on top of new pre-labeled 50ml tubes (labeled as “A” or “B”) and the suspensions were filtered. Each filter was washed with additional 5ml DMEM LG and the filtrate was then centrifuged for 10min at 500 x g, 21±2°C. The pellets were resuspended in 5ml DMEM LG. Next, a 40µm filter was placed on top of another set of new pre-labeled 50ml tubes (labeled as “A” or “B”) and the suspensions were filtered. Each filter was washed with additional 5ml DMEM LG and the filtrate was then centrifuged for 10min at 500 x g, 21±2°C. Each pellet was resuspended in 5ml StemMACS™ Complete growth medium (Miltenyi).

#### SVF cell counting and SVF seeding

NC-200 Nucleo-Counter was used to count the number of cells in each tube. The following parameters were recorded: viable cells/ml, dead cells /ml, viability (%), average cell size(µm) and total number of viable cells. Each tube was counted twice and an average of the two counts was calculated.

Next,  $2.6 \times 10^6$  cells from each tube were seeded in 75cm<sup>2</sup> flasks in duplicates and 15ml of StemMACS™ Complete growth medium were added to each flask. The flasks were incubated overnight to select for plastic adherent cells (ADSCs). The next day the flasks were washed to remove non-adherent cells and tissue debris, fresh medium was

added and cells were allowed to grow. Cells were harvested when one of the groups reached approximately 80% confluence.

#### Harvesting of P0

5 Cells were harvested and counted. The following parameters were recorded: viable cells/ml, dead cells/ml, viability (%), average cell size ( $\mu\text{m}$ ), total number of viable cells, and time from seeding to harvest (days). Each tube was counted twice and an average of the two counts was calculated.

#### 10 Immunophenotype - P0

Cells from each tube were analyzed by FACS for the following markers: CD73, CD90, CD45, CD31, and IgG1 as a control.

#### Results

15 **Tables 15** and **17** below and **Figures 8A-8B, 9A-9B** show cell counting data (average of two counts for each sample) immediately after SVF isolation and at passage 0 (P0). The standard deviation (SD) data are summarized in **Tables 16, 18**.

Table 15 – Cell count following SVF isolation

| Batch                        | EF137    |          | EF144    |          |
|------------------------------|----------|----------|----------|----------|
| <b>Sample</b>                | <b>A</b> | <b>B</b> | <b>A</b> | <b>B</b> |
| Viable cells/ml              | 8.56E+06 | 8.51E+06 | 2.59E+06 | 5.63E+06 |
| Dead cells/ml                | 2.72E+06 | 2.93E+06 | 5.64E+05 | 1.33E+06 |
| Viability %                  | 75.9     | 74.4     | 82.3     | 80.9     |
| Av. cell size (micrometer)   | 9.85     | 9.7      | 10.4     | 10.15    |
| Total number of viable cells | 4.28E+07 | 4.25E+07 | 1.30E+07 | 2.82E+07 |



Table 16 – SD of cell count following SVF isolation

| Batch                        | EF137    |          | EF144    |          |
|------------------------------|----------|----------|----------|----------|
| Sample                       | A        | B        | A        | B        |
| Viable cells/ml              | 2.47E+05 | 1.63E+05 | 2.55E+05 | 7.07E+04 |
| Dead cells/ml                | 6.36E+04 | 1.20E+05 | 1.47E+05 | 1.77E+05 |
| Viability %                  | 0.14     | 1.13     | 2.40     | 1.84     |
| Av. cell size (micrometer)   | 0.070711 | 0        | 0        | 0.070711 |
| Total number of viable cells | 1.24E+06 | 8.13E+05 | 1.27E+06 | 3.54E+05 |

Table 17 – Cell count at P0

| Batch                        | EF137    |          | EF144    |          |
|------------------------------|----------|----------|----------|----------|
| Sample                       | A        | B        | A        | B        |
| Viable cells/ml              | 4.81E+05 | 9.04E+05 | 1.30E+06 | 2.07E+06 |
| Dead cells/ml                | 1.32E+04 | 3.08E+04 | 7.79E+04 | 1.42E+05 |
| Viability %                  | 97.325   | 96.7     | 94.325   | 93.475   |
| Av. cell size (micrometer)   | 13.75    | 13.425   | 13.475   | 13.425   |
| Total number of viable cells | 2.41E+06 | 4.52E+06 | 6.50E+06 | 1.03E+07 |

5

Table 18 – SD of cell count at P0

| Batch                        | EF137    |          | EF144    |          |
|------------------------------|----------|----------|----------|----------|
| Sample                       | A        | B        | A        | B        |
| Viable cells/ml              | 2.08E+04 | 1.18E+05 | 8.60E+04 | 3.23E+05 |
| Dead cells/ml                | 8.49E+03 | 7.16E+03 | 5.09E+04 | 4.55E+04 |
| Viability %                  | 1.763283 | 0.374166 | 3.757104 | 2.478407 |
| Av. cell size (micrometer)   | 0.208167 | 0.095743 | 0.170783 | 0.15     |
| Total number of viable cells | 1.04E+05 | 5.90E+05 | 4.30E+05 | 1.61E+06 |

As can be seen from the tables and figures, cell counting data were essentially the same, and for some parameters even better, for samples that were not subjected to the red blood cell lysis (samples designated as “B”) and those subjected to the lysis step (samples designated as “A”), indicating that omission of the lysis step does not negatively affect the growth of the cells.

Advantageously, at P0, samples that were not subjected to the red blood cell lysis reached 70-80% confluency faster than samples that were subjected to the lysis step.

**Table 19** summarizes the immunophenotype data (marker expression) at passage 0.

As can be seen from the table, marker expression was essentially the same for samples not subjected to the red blood cell lysis and for samples that were subjected to the lysis step, indicating that omission of this step does not negatively affect the phenotype of the obtained cells.

Table 19 – Marker expression (%) at P0

| Batch  | EF137 |       | EF144 |       |
|--------|-------|-------|-------|-------|
| Sample | A     | B     | A     | B     |
| CD73   | 99.9  | 99.85 | 99.9  | 99.9  |
| CD90   | 99.65 | 99.9  | 99.95 | 99.85 |
| CD45   | 0.25  | 0.3   | 0.3   | 0.25  |
| CD31   | 5.85  | 1.9   | 3.75  | 4.15  |

To conclude, it was found that even though a red blood cell lysis buffer is not applied, the resulting ADSC sample grows as effectively as a sample isolated according to standard methods employing red blood cell lysis.

#### **Example 4- Effect of initial tissue volume on the yield of stromal vascular fraction (SVF) and adipose-derived stem cells (ADSCs)**

The amount of ADSCs that can be obtained from a lipoaspirated tissue sample depends, among others, on the initial volume of the lipoaspirated tissue sample. For therapeutic applications such as treating multiple sclerosis as described herein, it is suggested that at least  $10^5$  ADSCs be obtained, or even at least  $10^6$  ADSCs.

The following study aimed at defining a minimum volume of fat tissue (lipoaspirated tissue) that can be used in order to obtain an amount of ADSCs that is

sufficient for therapeutic purposes such as treating multiple sclerosis according to the present invention, and at evaluating possible changes to the production process that may improve the yield in cases where volumes lower than 100ml are available for processing.

5        **Study design**

Three different batches of human lipoaspirated tissue were obtained. From each batch, samples of 5, 10, 20, 50 and 150ml were washed with PBS and placed in freezing bags. DMSO was added at a final concentration of 10% and the samples were stored in liquid nitrogen until use.

10

**SVF production**

All samples were thawed and processed to obtain SVF without applying red blood cell lysis, as described in Examples 1 and 3 above. The samples of 5, 10, 20 and 50ml were processed without applying filtration (i.e., the steps of filtering through a 100µm  
15 filter and subsequently through a 40µm filter were omitted, in addition to the omission of the red blood cell lysis).

**Cell culture**

The SVF fractions obtained from the 20, 50 and 150ml samples were seeded at a  
20 concentration of  $35 \times 10^3 / \text{cm}^2$ . The SVF fractions obtained from the 5 and 10ml samples were seeded at a concentration of  $\sim 4 \times 10^3$  cells/ $\text{cm}^2$ . Following overnight incubation to select for plastic adherent cells (ADSCs), the flasks were washed, fresh medium was added, and the cells were grown in StemMACS™ Complete medium to  $\sim 80\%$  confluency. At this stage the cell passage was defined as P#0. Cells were then trypsinized, harvested,  
25 seeded in fresh flasks at a concentration of  $5 \times 10^3$  cells/ $\text{cm}^2$ , and grown again to  $\sim 80\%$  confluency to the next passage, defined as P#1. Cells were then trypsinized, harvested, and kept frozen at a concentration of  $\sim 5 \times 10^6 / \text{ml}$  in 1ml cryotubes until use.

In addition, during the processing of the 50ml samples, a large number of tissue aggregates were observed following tissue digestion and centrifugation, and it was  
30 decided to examine if the aggregates can also yield mesenchymal stem cells when processed separately. The aggregates were collected and seeded in separate flasks and incubated overnight to select for plastic-adherent cells. The non-adherent cells were



washed and the remaining sample was further processed in the same manner as the other samples.

Analysis:

5            Cells were thawed and the number of cells, cell viability and cell diameter were determined immediately after thawing. For FACS analysis cells were allowed to recover overnight (1 frozen vial seeded in a 175 cm<sup>2</sup> flask) prior to the analysis.

Results

10           Tables 20-22 below and **Figures 10A-C, 11A-C, 12A-C** show cell counting data for each sample immediately after SVF isolation and at passages 0 and 1 (P#0, P#1).

Table 20

| 1 <sup>st</sup> batch                            |       |      |        |       |                    |        |
|--|-------|------|--------|-------|--------------------|--------|
| Total number of viable cells (x10 <sup>6</sup> ) |       |      |        |       |                    |        |
|  | 5ml   | 10ml | 20ml   | 50ml  | 50ml<br>Aggregates | 150ml  |
| SVF  | 3.34  | 1.97 | 3.27   | 3.27  | NA                 | 11.00  |
| P#0  | 1.81  | 0.49 | 9.51   | 0.75  | 6.00               | 11.50  |
| P#1  | 36.80 | 5.90 | 152.68 | 12.54 | 114.73             | 124.80 |

15

Table 21

| 2 <sup>nd</sup> batch                            |       |       |       |        |                    |       |
|--|-------|-------|-------|--------|--------------------|-------|
| Total number of viable cells (x10 <sup>6</sup> ) |       |       |       |        |                    |       |
|  | 5ml   | 10ml  | 20ml  | 50ml   | 50ml<br>Aggregates | 150ml |
| SVF  | 0.99  | 2.53  | 2.71  | 6.70   | NA                 | 30.28 |
| P#0  | 0.89  | 2.43  | 1.97  | 9.77   | 10.90              | 19.70 |
| P#1  | 13.06 | 30.50 | 21.50 | 100.25 | 156.56             | 98.00 |

Table 22

| 3 <sup>rd</sup> batch |  |      |        |       |                 |       |
|-----------------------|--|------|--------|-------|-----------------|-------|
|                       | Total number of viable cells (x10 <sup>6</sup> ) |      |        |       |                 |       |
|                       | 5ml  | 10ml | 20ml   | 50ml  | 50ml Aggregated | 150ml |
| SVF                   | 0.61   | 0.53 | 7.13   | 9.03  | NA              | 8.70  |
| P#0                   | 0.82   | 0.72 | 7.65   | 10.30 | 4.10            | 9.30  |
| P#1                   | 4.43   | 4.78 | 102.40 | 99.00 | 72.78           | 68.60 |

Large variability was seen in the SVF yield between the three different batches. In addition, the number of cells in the SVF fraction did not always correlate with the number of cells obtained at P#0. However, once a selected MSC population was harvested (P#0), the further expansion to P#1 correlated with the number of MSC cells at P#0, and at P#1 the number of cells of a given batch correlated with the number of cells of this batch at P#0.

As described above, the 50 ml samples were not filtered and large aggregates were observed. The aggregates were collected and seeded separately (rather than discarded, as normally done). The aggregates produced a large number of MSCs, and therefore it was concluded that it is advantageous to keep and culture aggregates for yield increase.

FACS analysis:

The P#1 samples of the three batches were harvested and cryopreserved at a concentration of ~5x10<sup>6</sup> cells/ml. The cells were then thawed, seeded overnight with StemMACS™ Complete, harvested and analyzed by FACS. The markers that were analyzed are listed in Table 23. The results of the analysis are specified in Tables 24-27.

Table 23 – markers for FACS analysis

| Markers   |          |
|-----------|----------|
| CD73-PE   | Positive |
| CD90-PE   |          |
| CD105-PE  |          |
| CD44-FITC |          |

|           |          |
|-----------|----------|
| HLA-DR-PE | Negative |
| CD34-PE   |          |
| CD45-PE   |          |
| CD11b-PE  |          |
| CD19-PE   |          |
| IgG1-PE   | Control  |
| IgG2a-PE  |          |
| IgG1-FITC |          |

5

Table 24 – FACS analysis – positive markers

| Volume          | Batch           | CD73-PE | CD90-PE | CD105-PE | CD44-FITC |
|-----------------|-----------------|---------|---------|----------|-----------|
| 5ml             | 1 <sup>st</sup> | 99.9    | 99.9    | 96.9     | 99.7      |
|                 | 2 <sup>nd</sup> | 99.8    | 99.8    | 95.0     | 98.8      |
|                 | 3 <sup>rd</sup> | 99.9    | 99.9    | 99.8     | 99.8      |
|                 | Average         | 99.9    | 99.9    | 97.2     | 99.4      |
| 10ml            | 1 <sup>st</sup> | 99.9    | 99.6    | 98.5     | 98.7      |
|                 | 2 <sup>nd</sup> | 99.9    | 99.8    | 99.4     | 99.5      |
|                 | 3 <sup>rd</sup> | 99.9    | 99.9    | 99.8     | 99.6      |
|                 | Average         | 99.9    | 99.8    | 99.2     | 99.3      |
| 20ml            | 1 <sup>st</sup> | 99.9    | 99.9    | 98.5     | 99.3      |
|                 | 2 <sup>nd</sup> | 99.6    | 99.5    | 98.4     | 98.5      |
|                 | 3 <sup>rd</sup> | 99.9    | 99.9    | 99.8     | 99.7      |
|                 | Average         | 99.8    | 99.8    | 98.9     | 99.2      |
| 50ml            | 1 <sup>st</sup> | 99.9    | 99.9    | 99.4     | 99.2      |
|                 | 2 <sup>nd</sup> | 99.9    | 99.9    | 99.9     | 99.0      |
|                 | 3 <sup>rd</sup> | 99.7    | 99.8    | 99.4     | 99.5      |
|                 | Average         | 99.8    | 99.9    | 99.6     | 99.2      |
| 50ml Aggregated | 1 <sup>st</sup> | 99.9    | 99.9    | 99.5     | 99.1      |
|                 | 2 <sup>nd</sup> | 100.0   | 99.9    | 99.9     | 99.7      |
|                 | 3 <sup>rd</sup> | 99.8    | 99.6    | 95.9     | 98.9      |
|                 | Average         | 99.9    | 99.8    | 98.4     | 99.2      |
| 150ml           | 1 <sup>st</sup> | 99.9    | 99.9    | 99.9     | 99.7      |
|                 | 2 <sup>nd</sup> | 100.0   | 99.9    | 99.9     | 99.9      |
|                 | 3 <sup>rd</sup> | 99.9    | 99.8    | 99.5     | 99.9      |
|                 | Average         | 99.9    | 99.9    | 99.8     | 99.8      |



Table 25 – Positive markers -average and SD

|                    | CD73-PE | CD90-PE | CD105-PE | CD44-FITC |
|--------------------|---------|---------|----------|-----------|
| <b>Average</b>     |         |         |          |           |
| 5ml                | 99.9    | 99.9    | 97.2     | 99.4      |
| 10ml               | 99.9    | 99.8    | 99.2     | 99.3      |
| 20ml               | 99.8    | 99.8    | 98.9     | 99.2      |
| 50ml               | 99.8    | 99.9    | 99.6     | 99.2      |
| 50ml<br>Aggregated | 99.9    | 99.8    | 98.4     | 99.2      |
| 150ml              | 99.9    | 99.9    | 99.8     | 99.8      |
| <b>SD (n=3)</b>    |         |         |          |           |
| 5ml                | 0.1     | 0.1     | 2.4      | 0.6       |
| 10ml               | 0.0     | 0.2     | 0.7      | 0.5       |
| 20ml               | 0.2     | 0.2     | 0.8      | 0.6       |
| 50ml               | 0.1     | 0.1     | 0.3      | 0.3       |
| 50ml<br>Aggregated | 0.1     | 0.2     | 2.2      | 0.4       |
| 150ml              | 0.1     | 0.1     | 0.2      | 0.1       |

Table 26 – FACS analysis – negative markers

| Volume             | Batch           | HLA-DR-PE | CD34-PE | CD45-PE | CD11b-PE | CD19-PE |
|--------------------|-----------------|-----------|---------|---------|----------|---------|
| 5ml                | 1 <sup>st</sup> | 0.0       | 0.2     | 0.1     | 0.0      | 0.1     |
|                    | 2 <sup>nd</sup> | 0.2       | 7.1     | 2.4     | 0.4      | 0.8     |
|                    | 3 <sup>rd</sup> | 0.3       | 0.3     | 0.1     | 0.0      | 0.1     |
|                    | Average         | 0.2       | 2.5     | 0.9     | 0.1      | 0.3     |
| 10ml               | 1 <sup>st</sup> | 0.2       | 0.6     | 0.2     | 0.1      | 0.1     |
|                    | 2 <sup>nd</sup> | 0.1       | 35.6    | 6.5     | 1.0      | 4.8     |
|                    | 3 <sup>rd</sup> | 0.3       | 9.3     | 6.9     | 0.1      | 8.6     |
|                    | Average         | 0.2       | 15.2    | 4.5     | 0.4      | 4.5     |
| 20ml               | 1 <sup>st</sup> | 0.2       | 0.6     | 0.2     | 0.1      | 0.0     |
|                    | 2 <sup>nd</sup> | 0.3       | 68.8    | 5.0     | 0.4      | 1.3     |
|                    | 3 <sup>rd</sup> | 0.1       | 2.1     | 0.8     | 0.2      | 1.3     |
|                    | Average         | 0.2       | 23.8    | 2.0     | 0.2      | 0.9     |
| 50ml               | 1 <sup>st</sup> | 0.1       | 19.7    | 0.8     | 0.2      | 1.8     |
|                    | 2 <sup>nd</sup> | 0.2       | 41.7    | 12.8    | 0.2      | 12.4    |
|                    | 3 <sup>rd</sup> | 0.1       | 9.4     | 0.3     | 0.2      | 0.9     |
|                    | Average         | 0.1       | 23.6    | 4.6     | 0.2      | 5.0     |
| 50ml<br>Aggregated | 1 <sup>st</sup> | 0.2       | 28.4    | 7.0     | 0.2      | 9.4     |
|                    | 2 <sup>nd</sup> | 0.2       | 78.4    | 33.6    | 2.1      | 12.9    |
|                    | 3 <sup>rd</sup> | 0.1       | 18.8    | 0.8     | 0.6      | 0.1     |
|                    | Average         | 0.2       | 41.9    | 13.8    | 1.0      | 7.5     |
| 150ml              | 1 <sup>st</sup> | 0.0       | 7.0     | 4.2     | 0.0      | 0.6     |

|  |                 |     |      |     |     |     |
|--|-----------------|-----|------|-----|-----|-----|
|  | 2 <sup>nd</sup> | 0.1 | 23.2 | 4.9 | 0.1 | 4.2 |
|  | 3 <sup>rd</sup> | 0.2 | 4.6  | 1.1 | 0.5 | 0.3 |
|  | Average         | 0.1 | 11.6 | 3.4 | 0.2 | 1.7 |

Table 27 – negative markers- average and SD

|                 | HLA-DR-PE | CD34-PE | CD45-PE | CD11b-PE | CD19-PE |
|-----------------|-----------|---------|---------|----------|---------|
| <b>Average</b>  |           |         |         |          |         |
| 5ml             | 0.2       | 2.5     | 0.9     | 0.1      | 0.3     |
| 10ml            | 0.2       | 15.2    | 4.5     | 0.4      | 4.5     |
| 20ml            | 0.2       | 23.8    | 2.0     | 0.2      | 0.9     |
| 50ml            | 0.1       | 23.6    | 4.6     | 0.2      | 5.0     |
| 50ml Aggregated | 0.2       | 41.9    | 13.8    | 1.0      | 7.5     |
| 150ml           | 0.1       | 11.6    | 3.4     | 0.2      | 1.7     |
| <b>SD (n=3)</b> |           |         |         |          |         |
| 5ml             | 0.2       | 4.0     | 1.3     | 0.2      | 0.4     |
| 10ml            | 0.1       | 18.2    | 3.8     | 0.5      | 4.3     |
| 20ml            | 0.1       | 38.9    | 2.6     | 0.2      | 0.8     |
| 50ml            | 0.1       | 16.5    | 7.1     | 0.0      | 6.4     |
| 50ml Aggregated | 0.1       | 32.0    | 17.4    | 1.0      | 6.6     |
| 150ml           | 0.1       | 10.1    | 2.0     | 0.3      | 2.2     |

5 The positive markers showed a high percentage of mesenchymal stem cells (as defined by the ISCT guidelines) in all of the processed volumes from all of the three tested batches (Positive CD73, CD105, CD90, CD44).

The negative markers showed higher percentages than what is normally seen for adipose-derived mesenchymal stem cells, indicating the presence of hematopoietic progenitors as impurities. In a separate series of experiments cells were cultured for five  
10 (5) passages, and it was demonstrated that the negative markers are decreased as a function of passage.

In non-filtered samples tissue aggregates may trap more hematopoietic progenitors, which result in higher expression of CD34 as well as higher CD45 and CD19  
15 expressing cells. This assumption is supported by 50ml-aggregates cultures, which displayed the highest CD34 expression.

To conclude, despite the large variability, the results show that sufficient amounts of ADSCs for therapeutic applications such as treatment of MS as disclosed herein can be

obtained even from very low initial tissue volumes. To utilize the low initial volumes, certain adaptations to the production process may be applied, such as omission of filtration and culturing for at least 4 passages, in order to reduce loss of cells and obtain an ADSC population with sufficient purity.

5           If possible, it is suggested to use initial tissue volumes of at least 50ml. It is further suggested to apply a production process which includes filtration through a set of filters (but is devoid of red blood cell lysis, as disclosed herein), *inter alia*, to improve the purity of the ADSCs at earlier passages.

10           However, if the volume of a lipoaspirated tissue collected from a patient is less than 50ml, and it is not possible to collect more, the adapted process may be applied.

          While the present invention has been particularly described, persons skilled in the art will appreciate that many variations and modifications can be made. Therefore, the invention is not to be construed as restricted to the particularly described embodiments, and the scope and concept of the invention will be more readily understood by reference to  
15   the claims, which follow.



**CLAIMS**

1. A method of treating primary progressive multiple sclerosis comprising administering non-genetically modified human adipose-derived stem cells (hADSCs) into the central nervous system (CNS) of a subject in need thereof.
- 5 2. The method of claim 1, wherein the hADSCs are hADSCs obtained from human subcutaneous fat by:
  - (a) freezing a lipoaspirate;
  - (b) thawing the lipoaspirate and dissociating with a tissue-dissociation enzyme or by mechanical disruption;
  - 10 (c) pelleting a cellular fraction comprising the hADSCs by centrifugation and optionally washing the pellet with a suspension medium capable of supporting cell viability and subjecting the suspension to at least one additional centrifugation;
  - (d) resuspending the pellet obtained in step (c) in a suspension medium capable of supporting cell viability and selecting hADSCs from the population of cells in the  
15 resuspended pellet;
  - (e) optionally conducting at least one filtration prior to the hADSC selection; and
  - (f) optionally culturing the hADSCs for at least 3 passages.
- 20 3. The method of claim 2, wherein the hADSCs are hADSCs obtained from human subcutaneous fat by: (i) freezing a lipoaspirate; (ii) thawing the lipoaspirate and dissociating with a tissue-dissociation enzyme or by mechanical disruption; (iii) pelleting a cellular fraction comprising the hADSCs by centrifugation; (iv) washing the pellet with an isotonic buffer or culture medium and subjecting to an additional centrifugation; (v) resuspending the pellet obtained in step (iv) in an isotonic buffer or culture medium and conducting at least one filtration; (vi) selecting hADSCs from the  
25 population of cells in the resuspended pellet; and (vii) culturing the hADSCs for at least 3 passages.
4. The method of claim 2 or claim 3, wherein the cellular fraction comprising the hADSCs obtained following centrifugation is not exposed to a red blood cell lysis buffer.



5. The method of any one of the preceding claims, wherein the hADSCs are selected by adherence to the cell culture vessel.
6. A method of injecting human adipose-derived stem cells (hADSCs) into the central nervous system (CNS) of a subject in need thereof, the method comprising obtaining  
5 hADSCs from human subcutaneous fat by:
- (a) freezing a lipoaspirate;
  - (b) thawing the lipoaspirate and dissociating with a tissue-dissociation enzyme or by mechanical disruption;
  - (c) pelleting a cellular fraction comprising the hADSCs by centrifugation and  
10 optionally washing the pellet with a suspension medium capable of supporting cell viability and subjecting the suspension to at least one additional centrifugation;
  - (d) resuspending the pellet obtained in step (c) in a suspension medium capable of supporting cell viability and conducting at least one filtration;
  - (e) selecting hADSCs from the population of cells in the resuspended pellet;
  - 15 (f) optionally culturing the hADSCs for at least 3 passages; and
  - (g) injecting the hADSCs into the CNS of the subject.
7. A method for obtaining human adipose-derived stem cells (hADSCs) from human subcutaneous fat for administration to a subject in need thereof, the method consisting of:
- 20 (a) freezing a lipoaspirate;
  - (b) thawing the lipoaspirate and dissociating with a tissue-dissociation enzyme or by mechanical disruption;
  - (c) pelleting a cellular fraction comprising the hADSCs by centrifugation, and optionally washing the pellet with a suspension medium capable of supporting cell  
25 viability and subjecting the suspension to at least one additional centrifugation;
  - (d) resuspending the pellet obtained in step (c) in a suspension medium capable of supporting cell viability and conducting at least one filtration;
  - (e) selecting hADSCs from the population of cells in the resuspended pellet; and
  - (f) optionally culturing the hADSCs for at least 3 passages prior to their  
30 administration to the subject.

8. The method of claim 6 or claim 7, wherein the hADSCs are selected by adherence to a tissue culture vessel.
9. The method of claim 6 or claim 7, wherein the subject is suffering from multiple sclerosis (MS).
- 5 10. The method of claim 9, wherein the multiple sclerosis is progressive MS.
11. The method of claim 10, wherein the progressive MS is secondary progressive MS.
12. The method of claim 10, wherein the progressive MS is primary progressive MS.
13. The method of any one of claims 2-12, wherein said freezing is carried out at  $-80^{\circ}\text{C}$  followed by vapor phase liquid nitrogen.
- 10 14. The method of any one of claims 2-13, wherein the tissue-dissociation enzyme is selected from a collagenase, a dispase or a combination thereof.
15. The method of claim 14, wherein the tissue-dissociation enzyme is a collagenase.
16. The method of any one of the preceding claims, wherein the hADSCs are characterized by positive expression of CD44, CD73 and CD90 by at least 95% of the cells, positive expression of CD105 by at least 90% of the cells, and negative expression of CD45, CD19, CD11b and HLA-DR by at least 95% of the cells.
- 15 17. The method of claim 16, wherein the hADSCs are characterized by positive expression of CD44, CD73 and CD90 by at least 98% of the cells, positive expression of CD105 by at least 90% of the cells, and negative expression of CD45, CD19, CD11b and HLA-DR by at least 98% of the cells.
- 20 18. The method of claim 16, wherein the hADSCs are further characterized by positive expression of CD34 by 1-10% of the cells.
19. The method of claim 16, wherein at least 50% of the cells are positive for CD105, CD73, CD44 and CD90, and negative for CD45, CD19, CD11b and HLA-DR.
- 25 20. The method of any one of the preceding claims, wherein the hADSCs are hADSCs cultured to a passage number between 3-10 prior to their administration.





21. The method of claim 20, wherein the hADSCs are hADSCs cultured to a passage number between 3-5 prior to their administration.
22. The method of any one of the preceding claims, wherein the hADSCs are administered once.
- 5 23. The method of any one of claims 1-21, wherein the hADSCs are administered more than once.
24. The method of claim 23, wherein the hADSCs are administered once every 2-8 months.
25. The method of claim 23, wherein the hADSCs are administered once every 3-12  
10 months.
26. The method of any one of the preceding claims, wherein administering the hADSCs is by intrathecal administration.
27. The method of any one of claims 1-25, wherein administering the hADSCs is by intraventricular or intracerebroventricular (ICV) administration.
- 15 28. The method of any one of the preceding claims, wherein the hADSCs are autologous.
29. The method of any one of claims 1-27, wherein the hADSCs are allogeneic.
30. The method of any one of the preceding claims, wherein administering the hADSCs comprises administering about  $10^5$  –  $3 \times 10^8$  cells per one administration.
31. A pharmaceutical composition comprising non-genetically modified human adipose-  
20 derived stem cells (hADSCs), for use in the treatment of primary progressive multiple sclerosis by administration into the central nervous system (CNS).

1/9

**Figure 1****Figure 2**

2/9

**Figure 3****Figure 4**



3/9




Figure 5






Figure 6


4/9

**Figure 7**

5/9




**Figure 8A**




**Figure 8B**



6/9



**Figure 9A**



**Figure 9B**

7/9




Figure 10A




Figure 10B




Figure 10C

8/9




Figure 11A




Figure 11B




Figure 11C



9/9




Figure 12A




Figure 12B




Figure 12C